IDX184 is a potent, orally active, targeted HCV polymerase inhibitor and nucleoside polymerase.IDX184 effectively inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM). IDX184 is a liver-targeted nucleotide prodrug with anti-HCV activity that inhibits HCV NS5B polymerase and can be used in combination with pegylated interferon-α2a and ribavirin for the primary treatment of chronic hepatitis C. It has been shown to inhibit HCV polymerase and nucleoside polymerase.

HCV polymerase:0.31 μM (IC50), HCV polymerase:52.3 nM (Ki)

IDX184, a liver-targeted prodrug of the nucleotide 2′-MeG-MP, serves as a hepatitis C virus polymerase inhibitor with liver-specific targeting.[1]
IDX184 is not toxic (CC50>100μM) in any tested cell line.[2]
IDX184 is a second-generation, orally bioavailable nucleotide prodrug designed to provide increased anti-HCV efficacy and safety versus the parent nucleoside. In HCV replicon testing, IDX184 is the most potent inhibitor (EC50=0.3-0.45 μM) compared to any of the 2’ or 4’ modified nucleosides (EC50=4-6 μM) and is also highly inhibitory in the JFH-1 infectious system (EC50=0.06-0.11 μM).[2]